Modulation of neutrophil motility by curcumin: Implications for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 503-515

  Larmonier, C B ^a   Midura Kiela, M T ^a   Ramalingam, R ^b   Laubitz, D ^a   Janikashvili, N ^a   Larmonier, N ^a,b   Ghishan, F K ^a   Kiela, P R ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

chemokinesis; chemotaxis; IL 8; inflammation; KC; MIP 2; PMN

Indexed keywords

CURCUMIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; F ACTIN; INTERLEUKIN 1BETA; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL POLARITY; CHEMOKINESIS; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENTERITIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CHEMOKINE CCL3; CHEMOTAXIS, LEUKOCYTE; COLON; CURCUMIN; DISEASE MODELS, ANIMAL; HUMANS; INTESTINAL MUCOSA; MACROPHAGES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; NEUTROPHILS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 78651323622     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21391     Document Type: Article

References (55)

1. Marks DJ, Segal AW,. Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol. 2008; 214: 260-266.
2. Rahman FZ, Marks DJ, Hayee BH, et al. Phagocyte dysfunction and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1443-1452.
3. Saverymuttu SH, Peters AM, Lavender JP, et al. Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology. 1983; 85: 1333-1339.
4. Wiedow O, Meyer-Hoffert U,. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med. 2005; 257: 319-328.
5. Sandborn WJ, Targan SR,. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002; 122: 1592-1608.
6. Busch-Petersen J,. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem. 2006; 6: 1345-1352.
7. Buanne P, Di Carlo E, Caputi L, et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol. 2007; 82: 1239-1246.
8. Farooq SM, Stillie R, Svensson M, et al. Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther. 2009; 329: 123-129.
9. Natsui M, Kawasaki K, Takizawa H, et al. Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats. J Gastroenterol Hepatol. 1997; 12: 801-808.
10. Palmen MJ, Dijkstra CD, van der Ende MB, et al. Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin Exp Immunol. 1995; 101: 351-356.
11. Buell MG, Berin MC,. Neutrophil-independence of the initiation of colonic injury. Comparison of results from three models of experimental colitis in the rat. Dig Dis Sci. 1994; 39: 2575-2588.
12. Yamada T, Zimmerman BJ, Specian RD, et al. Role of neutrophils in acetic acid-induced colitis in rats. Inflammation. 1991; 15: 399-411.
13. Kuhl AA, Kakirman H, Janotta M, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology. 2007; 133: 1882-1892.
14. Sharma RA, Gescher AJ, Steward WP,. Curcumin: the story so far. Eur J Cancer. 2005; 41: 1955-1968.
15. Joe B, Vijaykumar M, Lokesh BR,. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004; 44: 97-111.
16. Jagetia GC, Aggarwal BB,. "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007; 27: 19-35.
17. Kim GY, Kim KH, Lee SH, et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol. 2005; 174: 8116-8124.
18. Bhaumik S, Jyothi MD, Khar A,. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 2000; 483: 78-82.
19. Yadav VS, Mishra KP, Singh DP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005; 27: 485-497.
20. Cuendet M, Pezzuto JM,. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact. 2000; 17: 109-157.
21. Ammon HP, Anazodo MI, Safayhi H, et al. Curcumin: a potent inhibitor of leukotriene B4 formation in rat peritoneal polymorphonuclear neutrophils (PMNL). Planta Med. 1992; 58: 226.
22. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol. 2007; 7: 333-342.
23. Zhang M, Deng C, Zheng J, et al. Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol. 2006; 6: 1233-1242.
24. Jiang H, Deng CS, Zhang M, et al. Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol. 2006; 12: 3848-3853.
25. Zhang M, Deng CS, Zheng JJ, et al. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin. 2006; 27: 1071-1077.
26. Ukil A, Maity S, Karmakar S, et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003; 139: 209-218.
27. Salh B, Assi K, Templeman V, et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol. 2003; 285: G235-243.
28. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology. 2002; 123: 1912-1922.
29. Venkataranganna MV, Rafiq M, Gopumadhavan S, et al. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol. 2007; 13: 1103-1107.
30. Moss AC,. Curcumin for maintenance therapy in ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 642; author reply 642.
31. Jian YT, Mai GF, Wang JD, et al. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol. 2005; 11: 1747-1752.
32. Billerey-Larmonier C, Uno JK, Larmonier N, et al. Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis. 2008; 14: 780-793.
33. Hu M, Du Q, Vancurova I, et al. Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen-activated protein kinase pathway. Crit Care Med. 2005; 33: 2571-2578.
34. Takahashi M, Ishiko T, Kamohara H, et al. Curcumin (1,7-bis(4-hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione) blocks the chemotaxis of neutrophils by inhibiting signal transduction through IL-8 receptors. Mediators Inflamm. 2007; 2007: 10767.
35. Whitehead RH, VanEeden PE, Noble MD, et al. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci U S A. 1993; 90: 587-591.
36. Heit B, Kubes P,. Measuring chemotaxis and chemokinesis: the under-agarose cell migration assay. Sci STKE. 2003; 2003: PL5.
37. MacDermott RP,. Chemokines in the inflammatory bowel diseases. J Clin Immunol. 1999; 19: 266-272.
38. Pender SL, Chance V, Whiting CV, et al. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model. Gut. 2005; 54: 1114-1120.
39. Ohtsuka Y, Lee J, Stamm DS, et al. MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine. Gut. 2001; 49: 526-533.
40. Heit B, Tavener S, Raharjo E, et al. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol. 2002; 159: 91-102.
41. Ferrandi C, Ardissone V, Ferro P, et al. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. J Pharmacol Exp Ther. 2007; 322: 923-930.
42. Hannigan MO, Huang CK, Wu DQ,. Roles of PI3K in neutrophil function. Curr Top Microbiol Immunol. 2004; 282: 165-175.
43. Lin JK,. Molecular targets of curcumin. Adv Exp Med Biol. 2007; 595: 227-243.
44. Funk JL, Frye JB, Oyarzo JN, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. 2006; 54: 3452-3464.
45. Funk JL, Oyarzo JN, Frye JB, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod. 2006; 69: 351-355.
46. Vandal K, Rouleau P, Boivin A, et al. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide. J Immunol. 2003; 171: 2602-2609.
47. Lopez S, Seveau S, Lesavre P, et al. CD43 (sialophorin, leukosialin) shedding is an initial event during neutrophil migration, which could be closely related to the spreading of adherent cells. Cell Adhes Commun. 1998; 5: 151-160.
48. Benard V, Bohl BP, Bokoch GM,. Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem. 1999; 274: 13198-13204.
49. Larmonier CB, Uno JK, Lee KM, et al. Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G1079-1091.
50. Hanai H, Sugimoto K,. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des. 2009; 15: 2087-2094.
51. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4: 1502-1506.
52. D'Odorico A, D'Inca R, Mestriner C, et al. Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease. Dig Dis Sci. 2000; 45: 1594-1600.
53. Lampinen M, Sangfelt P, Taha Y, et al. Accumulation, activation, and survival of neutrophils in ulcerative colitis: regulation by locally produced factors in the colon and impact of steroid treatment. Int J Colorectal Dis. 2008; 23: 939-946.
54. Anezaki K, Asakura H, Honma T, et al. Correlations between interleukin-8, and myeloperoxidase or luminol-dependent chemiluminescence in inflamed mucosa of ulcerative colitis. Intern Med. 1998; 37: 253-258.
55. Arseneau KO, Cominelli F,. Leukocytapheresis in ulcerative colitis: a possible alternative to biological therapy? Dig Liver Dis. 2009; 41: 551-552.